Get the Stockscreener App
16.47
0.18%
-0.03
Moonlake Immunotherapeutics stock is traded at $16.47, with a volume of 979.10K.
It is down -0.18% in the last 24 hours and down -15.63% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
See More
Previous Close:
$16.50
Open:
$16.31
24h Volume:
979.10K
Relative Volume:
0.83
Market Cap:
$1.40B
Revenue:
-
Net Income/Loss:
$-230.32M
P/E Ratio:
-4.6711
EPS:
-3.5259
Net Cash Flow:
$-196.04M
1W Performance:
-9.80%
1M Performance:
-15.63%
6M Performance:
+4.44%
1Y Performance:
-69.99%
1-Day Range:
$16.30
$16.67
1-Week Range:
$15.93
$17.77
52-Week Range:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
16.47 | 1.47B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Upgrade | Wolfe Research | Underperform → Outperform |
| Mar-19-26 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Jan-15-26 | Downgrade | Goldman | Neutral → Sell |
| Jan-09-26 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-03-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-02-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-01-25 | Downgrade | Goldman | Buy → Neutral |
| Sep-30-25 | Downgrade | Citigroup | Buy → Neutral |
| Sep-30-25 | Downgrade | Wolfe Research | Outperform → Underperform |
| Sep-29-25 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-29-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-29-25 | Downgrade | Stifel | Buy → Hold |
| Jul-28-25 | Initiated | Rothschild & Co Redburn | Neutral |
| May-19-25 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
Cormorant Asset Management (MLTX) discloses 4.35% MoonLake Immunotherapeutics stake - Stock Titan
T. Rowe Price (MLTX holder) discloses 5.3% MoonLake Immunotherapeutics position - Stock Titan
Deep Track reports 7.99M-share, 9.74% stake in MoonLake (MLTX) in 13G/A - Stock Titan
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
MLTX Stock Moves Higher As Traders Position For Late-Stage Trial Catalysts - Stocktwits
MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital - The Globe and Mail
MLTX LAWSUIT ALERT: Levi & Korsinsky Notifies MoonLake Immunother - The National Law Review
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’ - stocktwits.com
Avoiding Lag: Real-Time Signals in (MLTX) Movement - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 5.3%Time to Sell? - MarketBeat
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - stocktwits.com
MoonLake’s Sonelokimab Meets Primary Endpoint in Phase 3 PsA Trial - The Dermatology Digest
MoonLake’s nanobody boosts PsA indication hopes after Phase III success - Yahoo
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and MoonLake Immunotherapeutics (MLTX) - The Globe and Mail
MoonLake's nanobody clears Phase III test, but shares slip - The Pharma Letter
MoonLake Immunotherapeutics (MLTX) Stock Analysis: 61% Upside Potential Amid Biotech Innovations - directorstalkinterviews.com
Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate? - STAT
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event - Stocktwits
How Psoriatic Arthritis Trial Success and Q2 Losses Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st
MoonLake touts Phase III PsA data, but investors may have wanted more - FirstWord Pharma
Moonlake Immunotherapeutics Files For Mixed Shelf Offering, Size Not Disclosed - TradingView
Why is MoonLake Immunotherapeutics stock plunging today? By Investing.com - Investing.com India
MoonLake Immunotherapeutics Releases Q2 2026 Financial Results - AlphaStreet
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - benzinga.com
MoonLake's sonelokimab meets all endpoints in Phase 3 IZAR-1 psoriatic arthritis trial - Dealroom
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap DownHere's What Happened - MarketBeat
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win - Endpoints News
Traders Buy Large Volume of MoonLake Immunotherapeutics Call Options (NASDAQ:MLTX) - MarketBeat
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial - Fierce Biotech
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial - Dermatology Times
MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves - Kalkine Media
MoonLake Immunotherapeutics Announces Q2 2026 Financial Results and Positive Phase 3 IZAR-1 Trial Data for Sonelokimab in Psoriatic Arthritis - Kalkine Media
MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals - Moomoo
MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
MoonLake reports positive phase 3 psoriatic arthritis trial results By Investing.com - Investing.com Nigeria
MoonLake Immunotherapeutics 2Q 2026: Net loss $(61.8)M, EPS $(0.84) — 10-Q Summary - TradingView
MoonLake reports positive phase 3 psoriatic arthritis trial results - Investing.com
Why is MoonLake Immunotherapeutics stock plunging today? - Investing.com
MoonLake reports positive Phase 3 PsA data and $537 million cash - quiverquant.com
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results - The Manila Times
Press Release: MoonLake Announces Positive Topline Results From the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across All Clinical Endpoints, and Reports Second Quarter 2026 Financial Results - Moomoo
MoonLake Immunotherapeutics (MLTX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
MLTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown - Stocktwits
Certain Stock Options of MoonLake Immunotherapeutics are subject to a Lock-Up Agreement Ending on 8-AUG-2026. - marketscreener.com
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX - MarketBeat
Renaissance Technologies LLC Raises Stake in MoonLake Immunotherapeutics $MLTX - MarketBeat
MoonLake Immunotherapeutics Insiders Sold US$8.7m Of Shares Suggesting Hesitancy - Moomoo
MoonLake Immunotherapeutics (MLTX) Investor Outlook: Potential 60.92% Upside Sparks Interest - directorstalkinterviews.com
Investor Alert: Deadline Approaching to Join MoonLake Immunothera - The National Law Review
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):